YIELD10 BIOSCIENCE, INC. - Quarter Report: 2012 June (Form 10-Q)

Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

x      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

For the quarterly period ended June 30, 2012

 

OR

 

o         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                to                

 

Commission file number 001-33133

 

METABOLIX, INC.

 

 

(617) 583-1700

(Registrant’s telephone number, including area code)

 

 

(Former name, former address and former fiscal year, if changed since last report.)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x  No o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x  No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o  No x

 

The number of shares outstanding of the registrant’s common stock as of July 23, 2012 was 34,196,756.

 

 

Table of Contents

 

Metabolix, Inc.

Form 10-Q

For the Quarter Ended June 30, 2012

 

Table of Contents

 

		Page
Part I. Financial Information		3
Item
1.	Consolidated Financial Statements (Unaudited)	3
	Consolidated Balance Sheets at June 30, 2012 and December 31, 2011	3
	Consolidated Statements of Operations for the three and six months ended June 30, 2012 and 2011	4
	Consolidated Statements of Comprehensive Income for the three and six months ended June 30, 2012 and 2011	5
	Consolidated Statements of Cash Flows for the six months ended June 30, 2012 and 2011	6
	Notes to the Consolidated Financial Statements	7
2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
3.	Quantitative and Qualitative Disclosures About Market Risk	25
4.	Controls and Procedures	25
Part II. Other Information		25
Item
1.	Legal Proceedings	25
1A.	Risk Factors	26
2.	Unregistered Sales of Equity Securities and Use of Proceeds	26
3.	Defaults Upon Senior Securities	26
4.	Not Applicable	26
5.	Other Information	26
6.	Exhibits	26
SIGNATURES		27

 

2

Table of Contents

 

PART I.  FINANCIAL INFORMATION

 

ITEM 1.  CONSOLIDATED FINANCIAL STATEMENTS

 

METABOLIX, INC.

CONSOLIDATED BALANCE SHEETS

UNAUDITED

(in thousands, except share and per share data)

 

		June 30,			December 31,
		2012			2011
Assets
Current Assets:
Cash and cash equivalents		$	12,132		$	21,277
Short-term investments		36,029			55,578
Accounts receivable		508			146
Due from related parties		—			311
Unbilled receivables		521			304
Prepaid expenses and other current assets		597			823
Inventory		2,821			—
Total current assets		52,608			78,439
Restricted cash		622			622
Property and equipment, net		1,845			2,276
Long-term investments		11,763			1,503
Other assets		95			72
Total assets		$	66,933		$	82,912
Liabilities and Stockholders’ Equity
Current Liabilities:
Accounts payable		$	613		$	512
Accrued expenses		2,926			3,574
Current portion of deferred rent		165			165
Short-term deferred revenue		296			2,914
Total current liabilities		4,000			7,165
Deferred rent, net of current portion		138			221
Long-term deferred revenue		—			35,944
Other long-term liabilities		124			119
Total liabilities		4,262			43,449
Commitments and contingencies (Note 11)
Stockholders’ Equity:
Preferred stock ($0.01 par value per share); 5,000,000 shares authorized; no shares issued or outstanding		—			—
Common stock ($0.01 par value per share); 100,000,000 shares authorized at June 30, 2012 and December 31, 2011, 34,196,756 and 34,115,798 shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively		342			341
Additional paid-in capital		287,134			284,796
Accumulated other comprehensive loss		(35		)	(12		)
Accumulated deficit		(224,770		)	(245,662		)
Total stockholders’ equity		62,671			39,463
Total liabilities and stockholders’ equity		$	66,933		$	82,912

 

The accompanying notes are an integral part of these interim consolidated financial statements

 

3

Table of Contents

 

METABOLIX, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

UNAUDITED

(in thousands, except share and per share data)

 

		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2012			2011			2012			2011
Revenue:
Revenue from termination of ADM collaboration		$	—		$	—		$	38,885		$	—
Grant revenue		461			99			839			124
License fee and royalty revenue from related parties		89			92			134			393
Product revenue		373			—			387			—
Total revenue		923			191			40,245			517
Costs and expenses:
Cost of product revenue		437			—			492			—
Research and development		5,006			6,000			11,051			12,199
Selling, general, and administrative		3,437			4,196			7,836			7,983
Total costs and expenses		8,880			10,196			19,379			20,182
Income (loss) from operations		(7,957		)	(10,005		)	20,866			(19,665		)
Other income:
Interest income, net		9			23			26			43
Net income (loss)		$	(7,948	)	$	(9,982	)	$	20,892		$	(19,622	)
Net income (loss) per share:
Basic		$	(0.23	)	$	(0.33	)	$	0.61		$	(0.69	)
Diluted		$	(0.23	)	$	(0.33	)	$	0.61		$	(0.69	)
Number of shares used in per share calculations:
Basic		34,183,702			29,824,008			34,160,018			28,372,371
Diluted		34,183,702			29,824,008			34,264,428			28,372,371

 

The accompanying notes are an integral part of these interim consolidated financial statements

 

4

Table of Contents

 

METABOLIX, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

UNAUDITED

(in thousands)

 

		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2012			2011			2012			2011
Net income (loss):		$	(7,948	)	$	(9,982	)	$	20,892		$	(19,622	)
Other comprehensive income
Change in unrealized gain on investments		(5		)	(21		)	(18		)	(8		)
Change in foreign currency translation adjustment		(7		)	(4		)	(5		)	(4		)
Total other comprehensive income (loss)		(12		)	(25		)	(23		)	(12		)
Comprehensive income (loss)		$	(7,960	)	$	(10,007	)	$	20,869		$	(19,634	)

 

The accompanying notes are an integral part of these interim consolidated financial statements

 

5

Table of Contents

 

METABOLIX, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

UNAUDITED

(in thousands)

 

		Six Months Ended
		June 30,
		2012			2011
Cash flows from operating activities
Net income (loss)		$	20,892		$	(19,622	)
Adjustments to reconcile net income (loss) to cash used in operating activities:
Depreciation		718			770
Charge for 401(k) company common stock match		264			368
Stock-based compensation		2,083			2,442
Changes in operating assets and liabilities:
Receivables (billed and unbilled)		(579		)	(50		)
Due from related party		311			14
Prepaid expenses and other assets		203			304
Inventory		(2,821		)	—
Accounts payable		101			343
Accrued expenses		(675		)	(722		)
Deferred rent and other long-term liabilities		(78		)	(77		)
Deferred revenue		(38,562		)	931
Net cash used in operating activities		(18,143		)	(15,299		)
Cash flows from investing activities
Purchase of property and equipment		(287		)	(488		)
Purchase of investments		(47,935		)	(78,968		)
Proceeds from the sale and maturity of short-term investments		57,207			52,606
Net cash provided by (used in) investing activities		8,985			(26,850		)
Cash flows from financing activities
Proceeds from options exercised		19			48
Proceeds from public stock offering, net of offering costs of $2,336		—			49,357
Net cash provided by financing activities		19			49,405
Effect of exchange rate changes on cash and cash equivalents		(6		)	(4		)
Net increase (decrease) in cash and cash equivalents		(9,145		)	7,252
Cash and cash equivalents at beginning of period		21,277			12,526
Cash and cash equivalents at end of period		$	12,132		$	19,778

 

The accompanying notes are an integral part of these interim consolidated financial statements

 

6

Table of Contents

 

METABOLIX, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

UNAUDITED

 

(All dollar amounts, except per share amounts, are stated in thousands)

 

1. BASIS OF PRESENTATION

 

The accompanying consolidated financial statements are unaudited and have been prepared by Metabolix, Inc. (the “Company”) in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted. The year-end consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. The consolidated financial statements, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position and results of operations for the interim periods ended June 30, 2012 and 2011.

 

The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for any future period or the entire fiscal year. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2011, which are contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 12, 2012.

 

2. ACCOUNTING POLICIES

 

Inventory

 

During March 2012, the Company acquired raw material and finished goods inventory of biopolymer from Telles, LLC as described in Note 15.  The Company’s adopted inventory policies as a result of this transaction are to state inventory at the lower of cost or market and to value inventory using the average cost method.  The Company analyzes its inventory levels quarterly and writes down, to cost of product revenue, inventory that has become obsolete, inventory in excess of expected sales requirements or inventory that fails to meet commercial sales specifications.

 

Revenue Recognition

 

During March 2012, the Company initiated biopolymer product sales to customers for the first time.  The Company’s policy is to recognize revenue when evidence of an arrangement exists, title has passed or services have been rendered, the selling price is fixed or determinable and collectibility is reasonably assured.  Revenue from product sales to customers is recognized when all elements of the sale have been delivered.  All costs related to product shipment are recognized at time of shipment. During the Company’s six months ended June 30, 2012, it did not provide for rights of return to customers on product sales, except for situations where the product did not meet the technical specifications, and therefore does not record a provision for returns.

 

The Company intends to modify its standard sales terms and conditions during its fiscal quarter ending September 30, 2012 to provide customers with a limited right of return for a period of sixty days after product delivery. As a result of this new product return policy, the Company will defer recognition of product revenue until the sixty day period has lapsed.

 

There has been no other material change in accounting policies since the Company’s fiscal year ended December 31, 2011, as described in Note 2 to the consolidated financial statements included in its Annual Report on Form 10-K for the year then ended.

 

3. RECENT ACCOUNTING PRONOUNCEMENTS

 

In June 2011, the Financial Accounting Standards Board (“FASB”) issued an accounting standards update that eliminates the option to present components of other comprehensive income as part of the statement of changes in equity and requires an entity to present items of net income and other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. This guidance also requires an entity to present on the face of the financial statements reclassification adjustments from other comprehensive income to net income. This guidance became effective for fiscal years beginning after December 15, 2011.  In December 2011, the FASB issued an accounting standards update that defers the presentation requirement for other comprehensive income reclassifications on the face of the financial statements. The Company adopted the

 

7

Table of Contents

 

provisions of the guidance in its first quarter of 2012 and elected to present items of net income and other comprehensive income in two separate but consecutive statements.

 

4. BASIC AND DILUTED NET INCOME (LOSS) PER SHARE

 

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding. Common stock equivalents include stock options and warrants. Diluted net income per share is computed by dividing net income by the weighted-average number of dilutive common shares outstanding during the period. Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method.  In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported there is no difference in basic and diluted loss per share.

 

Shares used to calculate diluted earnings per share are as follows:

 

		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2012			2011			2012			2011
Numerator:
Net income (loss)		$	(7,948	)	$	(9,982	)	$	20,892		$	(19,622	)
Denominator:
Weighted average number of common shares outstanding		34,183,702			29,824,008			34,160,018			28,372,371
Effect of dilutive securities:
Stock options		—			—			104,410			—
Dilutive potential common shares		—			—			104,410			—
Shares used in calculating diluted earnings per share		34,183,702			29,824,008			34,264,428			28,372,371

 

The number of shares of potentially dilutive common stock related to options and warrants that were excluded from the calculation of dilutive shares since the inclusion of such shares would be anti-dilutive for the three and six months ended June 30, 2012 and 2011, respectively, are shown below:

 

		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2012		2011		2012		2011
Options		4,456,627		3,878,822		4,436,627		3,878,822
Warrants		4,086		4,086		4,086		4,086
Total		4,460,713		3,882,908		4,440,713		3,882,908

 

5. STOCK-BASED COMPENSATION

 

The Company recognized stock-based compensation expense, related to employee stock option awards, of $980 and $2,102 for the three and six months ended June 30, 2012, respectively.  Stock-based compensation expense, related to employee stock option awards, was $1,207 and $2,440 for the three and six months ended June 30, 2011, respectively. At June 30, 2012, there was approximately $6,507 of pre-tax stock-based compensation expense, net of estimated forfeitures, related to unvested awards not yet recognized which is expected to be recognized over a weighted average period of 2.83 years.

 

8

Table of Contents

 

A summary of option activity for the six months ended June 30, 2012 is as follows:

 

		Number of		Weighted Average
		Shares		Exercise Price
Outstanding at December 31, 2011		3,858,685		$	10.36
Granted		1,490,000		2.55
Exercised		(11,436	)	1.65
Cancelled		(628,655	)	9.91
Outstanding at June 30, 2012		4,708,594		7.97
Options exercisable at June 30, 2012		2,580,358		$	10.43
Weighted average grant date fair value of options granted during the six months ended June 30, 2012				$	1.75

 

For the six months ended June 30, 2012 and 2011, the Company determined the fair value of stock options using the Black-Scholes option pricing model with the following assumptions for option grants, respectively:

 

		Six Months Ended
		June 30,
		2012		2011
Expected dividend yield		—		—
Risk-free rate		0.67% - 1.15%		1.59% - 2.38%
Expected option term (in years)		5.3 – 5.5		5.5 – 5.6
Volatility		85% - 87%		77% - 78%

 

6. RESEARCH AND DEVELOPMENT

 

All costs associated with internal research and development as well as research and development services conducted for others are expensed as incurred. Research and development expenses include direct costs for salaries, employee benefits, subcontractors, facility related expenses, depreciation and stock-based compensation related to employees and non-employees involved in the Company’s research and development. Costs related to revenue-producing contracts are recorded as research and development expenses.

 

7. ADM COLLABORATION

 

In 2004, the Company signed a Technology Alliance and Option Agreement with ADM Polymer Corporation (“ADM Polymer”), a wholly-owned subsidiary of Archer Daniels Midland Company (“ADM”), to establish an alliance whereby the Company would provide technology, licenses and research and development services, and ADM Polymer would provide manufacturing services and capital necessary to produce biopolymers on a commercial scale.  The Technology Alliance and Option Agreement provided ADM with an option (the “Option”) to enter into a commercial alliance for further research, development, manufacture, use, and sale of biopolymers on the terms and conditions set forth in the Commercial Alliance Agreement.  In 2006, ADM exercised this Option, and the Technology Alliance and Option Agreement concluded.

 

The Commercial Alliance Agreement between Metabolix and ADM Polymer specified the terms and structure of the alliance. The primary function of this agreement was to establish the activities and obligations of the parties to commercialize PHA biopolymers, which have been marketed under the brand names Mirel™ and MveraTM. These activities included: the establishment of a joint venture company, Telles, LLC (“Telles”), to market and sell PHA biopolymers, the construction of a manufacturing facility capable of producing 110 million pounds of material annually (the “Commercial Manufacturing Facility”), the licensing of technology to Telles and to ADM, and the conducting of various research, development, manufacturing, sales and marketing, compounding and administrative services by the parties.

 

9

Table of Contents

 

Telles was formed to: (i) serve as the commercial entity to establish and develop the commercial market for PHA biopolymers, and conduct the marketing and sales in accordance with the goals of the commercial alliance, (ii) assist in the coordination and integration of the manufacturing, compounding and marketing activities, and (iii) administer and account for financial matters on behalf of the parties.  Metabolix and ADM each had a 50% ownership and voting interest in Telles.

 

Under the Technology Alliance and Option Agreement and Commercial Alliance Agreement various payments were made to Metabolix by ADM as shown in the table below.  All of these payments were recorded as deferred revenue on the Company’s balance sheet and were expected to be recognized on a straight line basis over a period of approximately ten years in which Metabolix would fulfill its contractual obligations during the Commercial Phase of the Commercial Alliance Agreement.

 

Upfront payment		$	3,000
Milestone payments		2,000
Support payments		22,050
Cost sharing payments for pre-commercial manufacturing plant construction and operations		11,835
Total		$	38,885

 

Under the Commercial Alliance Agreement ADM was permitted, under limited circumstances, to terminate the alliance if a change in circumstances that was not reasonably within the control of ADM made the anticipated financial return from the project inadequate or too uncertain. The agreement provided that, upon termination by ADM due to a change in circumstances, Metabolix would be permitted to continue to produce and sell PHA biopolymers, and ADM would be required to perform manufacturing services for the Company for a period of time following the termination (subject to certain payment obligations to ADM).  On January 9, 2012, ADM notified the Company that it was terminating the commercial alliance effective February 8, 2012.  ADM had recently undertaken a strategic review of its business investments and activities and made the decision to focus resources outside of Telles. As the basis for the decision, ADM indicated to the Company that the projected financial returns from the alliance were too uncertain.

 

The Commercial Alliance Agreement with ADM limited the rights of both ADM and the Company to work with other parties or alone in developing or commercializing certain PHAs produced through fermentation. These exclusivity obligations ended upon termination of the alliance.  Also, upon termination of the alliance, Metabolix intellectual property licenses to ADM Polymer and Telles ended, with Metabolix retaining all rights to its intellectual property.  ADM retained its Commercial Manufacturing Facility located in Clinton, Iowa, previously used to produce PHA biopolymers for Telles.

 

The Company has no further performance obligations in connection with the commercial alliance after its termination, and as a result, the $38,885 of deferred revenue was recognized by the Company during its fiscal quarter ended March 31, 2012.

 

After termination of the Commercial Alliance Agreement, the parties entered into a Settlement Agreement dated March 6, 2012 (the “Settlement Agreement”) in which the parties agreed to specific terms related to the winding up and dissolution of Telles.  Under this Settlement Agreement the Company purchased certain assets of the joint venture for $2,982, including Telles’s entire inventory, exclusive and perpetual rights to all of Telles’s trademarks, and all product registrations, certifications and approvals for Telles’s PHA biopolymers.  Pursuant to the Settlement Agreement, ADM relinquished any claims with respect to certain co-funded equipment previously acquired by Metabolix and situated at locations other than the Clinton, Iowa Commercial Manufacturing Facility, and Metabolix and Telles waived any rights to post-termination manufacturing and fermentation services under the Commercial Alliance Agreement. The Company assessed the market value of the various assets acquired from Telles under the Settlement Agreement and determined that the full amount of the $2,982 purchase price should be allocated to the raw material and biopolymer inventory.

 

Pursuant to the Settlement Agreement, Telles paid to ADM an amount equal to the aggregate cash balances of Telles totaling $3,778 on the date of the Settlement Agreement, minus $100 retained by Telles to settle any remaining trade obligations.  The Company believes the remaining trade obligations of Telles at the date of

 

10

Table of Contents

 

execution of the Settlement Agreement did not exceed $100.  In the event that ADM is required to repay to Telles or to pay to any creditor of Telles any amounts included in the $2,982 purchase price or the $3,678 distributed to ADM by Telles pursuant to the Settlement Agreement, Metabolix is obligated to reimburse ADM in an amount equal to 50% of such payments, provided that in no event would the amount to be so paid by Metabolix exceed the total of the $2,982 purchase price and the $3,678 Telles cash required to be so repaid or reimbursed by ADM. The Company is not aware of any such third party creditor claims, and believes that the likelihood that it will be required to reimburse ADM under this provision is remote and therefore no liability for this potential obligation is included in the Company’s balance sheet at June 30, 2012.

 

8. INCOME TAXES

 

The Company follows the accounting guidance related to income taxes including guidance which addresses accounting for uncertainty in income taxes. This guidance prescribes a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. It also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosures and transitions. The Company had no amounts recorded for any unrecognized tax benefits as of June 30, 2012 or December 31, 2011.

 

The tax years 2008 through 2011 remain open to examination by major taxing jurisdictions to which the Company is subject, which are primarily in the U.S.  Additionally, the Company can be audited for any loss year up to three years after the year in which the loss is utilized to offset taxable income.  This would include loss years prior to 2008.

 

The Company’s policy is to record estimated interest and penalties related to uncertain tax positions in income tax expense. As of June 30, 2012 and December 31, 2011, the Company had no accrued interest or penalties recorded related to uncertain tax positions.

 

At December 31, 2011 the Company had net operating loss (NOL) carryforwards for federal and state income tax purposes of $180,436 and $142,414, respectively. Included in the federal and state NOL carryforwards is approximately $19,201 of deduction related to the exercise of stock options subsequent to the adoption of amended accounting guidance related to stock-based compensation. This amount represents an excess tax benefit as defined under the amended accounting guidance related to stock-based compensation and has not been recorded as a deferred tax asset. The Company’s existing federal and state NOL carryforwards begin to expire in 2012. The Company also had available research and development credits for federal and state income tax purposes of approximately $4,502 and $3,200 respectively. The federal and state research and development credits will begin to expire in 2014 and 2016 respectively. As of December 31, 2011 the Company also had available investment tax credits for state income tax purposes of $117 which also began to expire in 2012. Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of NOL carryforwards and research and development credits. Under the applicable accounting standards, management has considered the Company’s history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of federal and state deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets.

 

Utilization of the NOL and research and development credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company has not currently completed an evaluation of ownership changes through December 31, 2011 to assess whether utilization of the Company’s NOL or research and development credit carryforwards would be subject to an annual limitation under section 382. To the extent an ownership change occurs in the future, the NOL and credit carryforwards may be subject to limitation.

 

11

Table of Contents

 

9. ACCRUED EXPENSES

 

Accrued expenses consisted of the following at:

 

		June 30, 2012			December 31, 2011
Employee compensation and benefits		$	1,715		$	1,740
Professional services		270			185
Contracted research and development		37			90
Intellectual property		159			240
Other		745			1,319
Total accrued expenses		$	2,926		$	3,574

 

10. SEGMENT INFORMATION

 

The accounting guidance for segment reporting establishes standards for reporting information on operating segments in annual financial statements. The Company operates in one segment, which is the business of developing and commercializing technologies for the production of polymers and chemicals in plants and in microbes. The Company’s chief operating decision-maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. As of June 30, 2012, less than 10% of the Company’s combined total assets were located outside of the United States and the reported net income outside of the United States for the three and six months ended June 30, 2012 was less than 10% of the combined net income of the consolidated Company.

 

11. COMMITMENTS AND CONTINGENCIES

 

Legal Proceedings

 

On February 17, 2012, a purported shareholder class action, Hilary Coyne v. Metabolix, Inc., Richard P. Eno, and Joseph Hill, Civil Action 1:12-cv-10318 (the “class action”), was filed in the United States District Court for the District of Massachusetts, naming the Company and certain officers of the Company as defendants. The class action alleges that the Company made material misrepresentations and/or omissions of material fact in the Company’s disclosures during the period from March 10, 2010 through its January 12, 2012 press release announcing that ADM had given notice of termination of the Telles joint venture for PHA biopolymers, all in violation of Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5. The class action seeks certification as a class action, compensatory damages in an unspecified amount, plaintiff’s costs and attorneys’ fees, and unspecified equitable or injunctive relief.

 

On March 7, 2012, a purported derivative lawsuit, Childs v. Kouba et al., Civil Action 12-0892 (the “derivative action”), was filed in Massachusetts Superior Court for Middlesex County, on behalf of the Company against members of the Company’s Board of Directors for alleged breaches of their fiduciary duties and based on a nearly identical set of alleged facts as those asserted in the class action.  The derivative action seeks compensatory damages in an unspecified amount, plaintiff’s costs and attorneys’ fees, and unspecified equitable or injunctive relief. The parties in the derivative action filed and the court granted a joint motion to stay the derivative action until after resolution of the anticipated motion to dismiss in the class action.

 

We are currently unable to assess the probability of loss or estimate a range of potential loss, if any, associated with these matters because they are at an early stage.

 

12. FAIR VALUE MEASUREMENTS

 

The Company has certain financial assets recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions.

 

The Company’s financial assets classified as Level 2 have been initially valued at the transaction price and subsequently valued typically utilizing third party pricing services. Because the Company’s investment portfolio

 

12

Table of Contents

 

may include securities that do not always trade on a daily basis, the pricing services use many observable market inputs to determine value including reportable trades, benchmark yields and benchmarking of like securities. The Company validates the prices provided by the third party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources. After completing the validation procedures, the Company did not adjust or override any fair value measurements provided by these pricing services as of June 30, 2012 or December 31, 2011.

 

The tables below present information about the Company’s assets that are measured at fair value on a recurring basis as of June 30, 2012 and December 31, 2011 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value.

 

		Fair value measurements at reporting date using
		Quoted prices in active
		markets for identical			Significant other			Significant
		assets			observable inputs			unobservable inputs			Balance as of
Description		(Level 1)			(Level 2)			(Level 3)			6/30/12
Cash equivalents:
Corporate debt		$	—		$	1,001		$	—		$	1,001
Government securities		—			1,025			—			1,025
Money market funds		8,032			—			—			8,032
Short-term investments:
Corporate debt		—			6,950			—			6,950
Government securities		—			29,079			—			29,079
Long-term investments:
Government securities		—			11,763			—			11,763
		$	8,032		$	49,818		$	—		$	57,850

 

		Fair value measurements at reporting date using
Description		Quoted prices in active markets for identical assets (Level 1)			Significant other observable inputs (Level 2)			Significant unobservable inputs (Level 3)			Balance as of 12/31/11
Cash equivalents:
Money market funds		$	18,262		$	—		$	—		$	18,262
Short-term investments:
Corporate debt		—			29,866			—			29,866
Government securities		—			25,712			—			25,712
Long-term investments:
Government securities		—			1,503			—			1,503
Total		$	18,262		$	57,081		$	—		$	75,343

 

In the tables above as of June 30, 2012 and December 31, 2011, all corporate debt securities were issued by financial institutions under the Temporary Liquidity Guarantee Program.

 

The Company considers investments purchased with an original maturity date of ninety days or more at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments.  All other investments are classified as long-term.

 

13. RELATED PARTIES

 

The Company engaged in various transactions with Tepha, Inc., a related party, and recorded $59 and $94 of license and royalty revenue during the three months and six months ended June 30, 2012, respectively.  During the three and six months ended June 30, 2011, the Company recorded license and royalty revenue from Tepha, Inc. of $92 and $393, respectively.  As of June 30, 2012 and December 31, 2011, the Company had no outstanding receivables due from Tepha.

 

13

Table of Contents

 

The Company had various transactions with its former alliance partner ADM, a related party, during the six months ended June 30, 2012 and 2011. The Company had an outstanding receivable balance of $203 due from ADM at December 31, 2011.

 

The Company also had various transactions with Telles. As of June 30, 2012, the Company had an outstanding receivable of $51 due from Telles. This amount has been fully reserved since it is uncertain whether remaining Telles funds will be sufficient to pay this receivable after settlement of third-party trade creditors.  The Company had an outstanding receivable balance of $108 due from Telles as of December 31, 2011. For more information on the Company’s related party transactions, please see Note 8 to the Company’s audited financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2011.

 

14. COMMON STOCK

 

Common Stock Issuances

 

During May 2011, the Company completed a public offering of 7,130,000 shares of its common stock at a price of $7.25 per share. Net proceeds were $49,333 after deducting underwriting discounts, commissions and offering costs of $2,360. The Company is using the proceeds from the offering for working capital and other general corporate purposes.

 

15. INVENTORY

 

During the quarter ended March 31, 2012 the Company acquired raw material and finished goods inventory of biopolymer from Telles, as a result of the termination of the joint venture with ADM.  As of June 30, 2012, inventory consisted of the following:

 

		June 30, 2012
Raw materials		$	714
Work-in-process		15
Finished goods		2,092
Total inventory		$	2,821

 

The Company did not own inventory at December 31, 2011.

 

16. RESTRUCTURING

 

In connection with the Telles termination, in the first quarter of 2012, the Company restructured its biopolymers business and downsized its operations to more appropriately align its 2012 business priorities and strategic plans with current cash and investment resources.  The Company has recognized $877 of restructuring charges through the six months ended June 30, 2012, as follows:

 

		Original Charges and Amounts Accrued			(Reversals) or Adjustments to Charges			Amounts Paid through June 30, 2012			Amounts Accrued at June 30, 2012
Employee severance, benefits and related costs		$	837		$	18		$	849		$	6
Contract termination costs		22			—			22			—
		$	859		$	18		$	871		$	6

 

14

Table of Contents

 

In July 2012, the Company signed a letter of intent to sublease to a third party its former corporate office located at One Kendall Square, Cambridge, Massachusetts beginning in August 2012.  Based on the prospective terms of the sublease, no additional restructuring charges are expected to be recorded in connection with the Company’s discontinued use of this facility.

 

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

(All dollar amounts are stated in thousands)

 

Forward Looking Statements

 

This quarterly report on Form 10-Q contains “forward-looking statements” within the meaning of 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In particular, statements contained in the Form 10-Q, including but not limited to, statements regarding our future results of operations and financial position, business strategy and plan prospects, projected revenue or costs and objectives of management for future research, development or operations, are forward-looking statements. These statements relate to our future plans, objectives, expectations and intentions and may be identified by words such as “may,” “will,” “should,” “expects,” “plans,” “anticipate,” “intends,” “target,” “projects,” “contemplates,” “believe,” “estimates,” “predicts,” “potential,” and “continue,” or similar words.

 

Although we believe that our expectations are based on reasonable assumptions within the limits of our knowledge of our business and operations, the forward-looking statements contained in this document are neither promises nor guarantees. Our business is subject to significant risk and uncertainties and there can be no assurance that our actual results will not differ materially from our expectations. These forward looking statements include, but are not limited to, statements concerning: future financial performance and position and management’s strategy, plans and objectives for research and development, product development, and commercialization of current and future products, including the commercialization of our biopolymer products. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated including, without limitation, risks related to our dependence on establishing collaborations or partnerships for the commercialization of our products, risks related to the development and commercialization of new and uncertain technologies, risks associated with our protection and enforcement of our intellectual property rights, as well as other risks and uncertainties set forth below under the caption “Risk Factors” in Part I, Item 1A, of our Annual Report on Form 10-K for the year ended December 31, 2011 and in Part II, Item 1A of this report.

 

The forward-looking statements and risk factors presented in this document are made only as of the date hereof and we do not intend to update any of these risk factors or to publicly announce the results of any revisions to any of our forward-looking statements other than as required under the federal securities laws.

 

Overview

 

Metabolix is an innovation-driven bioscience company focused on delivering sustainable solutions to the plastics, chemicals and energy industries. We have core capabilities in microbial genetics, fermentation process engineering, chemical engineering, polymer science, plant genetics and botanical science, and we have assembled these capabilities in a way that has allowed us to integrate our biotechnology research with real world chemical engineering and industrial practice. In addition, we have created an extensive intellectual property portfolio to protect our innovations and, together with our technology, to serve as a valuable foundation for future industry collaborations.

 

The markets for petroleum-based plastics, chemicals and fuels are among the largest in the global economy. Issues associated with the prolonged use of petroleum-based products include plastic waste management and pollution, limited fossil fuel availability and price volatility, and global warming and climate change. We believe that a substantial global market opportunity exists to develop and commercialize our technology to produce sustainable, renewable alternatives to petroleum-based products including advanced biopolymers, biobased industrial chemicals and bioenergy.

 

15

Table of Contents

 

Metabolix was formed to leverage the ability of natural systems to produce complex biopolymers from renewable resources. Metabolix has focused on a family of biopolymers found in nature called polyhydroxyalkanoates, or (“PHAs”), which occur naturally in living organisms and are chemically similar to polyesters. Metabolix has demonstrated the production of PHAs at the industrial scale to produce PHA biopolymers and biobased industrial chemicals, as well as production of PHB, a subclass of PHA biopolymer, in agriculturally significant crop plants.

 

In 2006, we entered into a commercial alliance with ADM Polymer Corporation (“ADM Polymer”), a wholly-owned subsidiary of Archer Daniels Midland Company (“ADM”), one of the largest agricultural processors in the world.

 

Under the commercial alliance, ADM was responsible for resin manufacturing, and Metabolix was primarily responsible for product development, compounding, marketing and sales. Through this alliance, the companies developed a proprietary, world scale microbial fermentation and recovery system for producing PHA biopolymers and established a joint venture company, Telles, LLC (“Telles”), to commercialize PHA biopolymer products. In 2009, ADM completed construction of the initial phase of its Commercial Manufacturing Facility located in Clinton, Iowa (“the Commercial Manufacturing Facility”). In 2010, the plant commenced operations and began production. In 2010 and 2011, Telles conducted significant product and commercial development activities with potential customers, marketed and sold product to customers under the tradenames Mirel™ and Mvera™, and developed a network of business partners and distributors. On January 9, 2012, ADM notified us that they were terminating the commercial alliance, effective as of February 8, 2012.  ADM undertook a strategic review of its business investments and activities and made the decision to focus resources outside of Telles.  As the basis for the decision, ADM indicated to us in January 2012 that the projected financial returns from the alliance were too uncertain.

 

Upon termination, ADM retained the Commercial Manufacturing Facility. We retained significant rights and assets associated with the PHA biopolymers business consistent with our intent to launch the business using a new commercial model, continuing business operations, marketing biopolymer products, and identifying alternate manufacturing capability. We hold exclusive rights to the Metabolix technology and intellectual property used in the joint venture. We have also acquired all of Telles’s product inventory and compounding raw materials, all product certifications and all product trademarks including MirelTM and MveraTM, and we retained all co-funded pilot plant equipment in locations outside of the Clinton plant. Metabolix has no obligations under the ledger account totaling $433 million which was funded by ADM to construct the Commercial Manufacturing Facility and to provide working capital to Telles.

 

In the first quarter of 2012, we restructured the biopolymers business and downsized our operations to more appropriately align our 2012 business priorities and strategic plans with current cash and investment resources. Although the restructuring was done primarily through employee termination, we retained a core team in our biopolymers group to provide continuity with technology, manufacturing process, and markets. In the second quarter of 2012, we continued the launch of mirel biopolymers with sales of inventory to existing customers and supply of product samples to potential customers for new applications. We have continued to work closely with customers during this transition to understand their product needs and to match them to available inventory. In addition, we have opened constructive discussions with alternative manufacturing and commercialization partners for biopolymers. Through Telles, we learned extremely valuable information about how customers and brand owners envision the use of PHA biopolymers in their products. Based on these interactions, we remain confident that Metabolix biopolymers provide an important solution to those wishing to reduce dependence on petroleum, reduce plastic waste in the environment, and utilize new solutions to meet sustainable packaging goals.

 

In 2012, our primary objectives are to advance business discussions with third parties with the goal of establishing a new commercial model for our PHA biopolymers, to work closely with our core customers to provide product from existing inventory during the transition phase and ensure ongoing development of PHA biopolymer products, to narrow our market development focus to high value market segments as the foundation to successfully build the business, and to establish a new manufacturing and supply chain properly sized to our business.

 

On July 26, 2012 we announced that we signed a letter of intent (“LOI”) with Antibióticos S.A. (“Antibioticos”) for production of MirelTM biopolymer resin. We expect to work closely with Antibioticos to complete the manufacturing, economic and engineering feasibility studies required to sign a contract manufacturing agreement. We expect that Antibioticos will begin producing demonstration quantities of Mirel biopolymer resin in early 2013.

 

16

Table of Contents

 

With the implementation of a new supply chain plan now underway, we expect to have productive discussions with customers to bridge existing biopolymer inventory to new commercial supply in 2013 and to continue our product development in high value-added applications.

 

For our second platform we are developing C4 and C3 chemicals from biobased sources, not the fossil fuels that are currently used to produce most industrial chemicals today. During 2009 we completed all work under our U.S. Department of Commerce National Institute of Standards and Technology grant, a $2 million grant aimed at producing C4 chemicals from renewable sources. We were able to achieve all of the technical milestones outlined in this grant. In 2010, we continued to scale up our C4 chemicals technology and continued efforts on chemical recovery and purification. We made progress toward production of biobased gamma-butyrolactone (“GBL”) samples for shipment to potential customers and we expanded exploratory partnership discussions.

 

In 2011, Metabolix and CJ CheilJedang (“CJ”) announced a joint development agreement to continue to advance and refine our production technology and assess investment options for the commercialization of biobased C4 chemicals via fermentation. The two companies are collaborating closely to develop a detailed market and economic analysis examining all aspects of an investment to commercialize biobased C4 chemicals. In the second quarter of 2012, we continued to advance our technology and engaged in discussions with prospective C4 chemicals customers.

 

The Company believes that developing and commercializing biobased C3 chemicals could represent another attractive market for our technology.  In the second quarter of 2012, we successfully scaled-up recovery of acrylic acid from dried biomass using the “FAST” process in our Cambridge laboratory and started shipping sample quantities of dried biomass for conversion to biobased acrylic acid for customer evaluation.  In the second half of 2012, we plan to continue fermentation scale up, engineering of microbial strains, and development and optimization of our FAST recovery technology to produce biobased industrial chemicals to meet or exceed chemical industry specifications for quality and purity.

 

Our third technology platform, crop-based businesses, which is at an early stage, is an innovative biorefinery system which uses plant crops to co-produce PHAs that can subsequently be recovered as bioplastics or biobased chemicals while also generating bioenergy or biofuels in an integrated biorefinery. For this system, we intend to extract polymer from the engineered plant crop, so that the remaining plant material can be used as a biomass feedstock for the production of bioenergy products including electricity and biofuel. In 2010, we expanded our recovery technology to enable the production of industrial chemicals from this platform. Our crop research has included tobacco, as well as oilseed, specifically camelina, sugarcane and switchgrass. In 2012 we plan to continue to advance research under a $6 million grant awarded by the U.S. Department of Energy to produce PHB in switchgrass, to co-produce densified biomass for fuel and to produce value-added crotonic acid.  We expect to continue utilization of government grants and collaborations with third parties to fund and advance our crop program.

 

As of June 30, 2012, we had an accumulated deficit of $224,770 and total stockholders’ equity was $62,671.

 

Collaborative Arrangements

 

Our strategy for collaborative arrangements is to retain substantial participation in the future economic value of our technology while receiving current cash payments to offset research and development costs and working capital needs. By their nature, these agreements are complex and have multiple elements that cover a variety of present and future activities.

 

17

Table of Contents

 

ADM Collaboration

 

In 2004, we signed a Technology Alliance and Option Agreement with ADM Polymer Corporation (“ADM Polymer”), a wholly-owned subsidiary of ADM, to establish an alliance whereby we would provide technology, licenses and research and development services, and ADM would provide manufacturing services and capital necessary to produce biopolymers on a commercial scale.  The Technology Alliance and Option Agreement provided ADM with an option (the “Option”) to enter into a commercial alliance for further research, development, manufacture, use, and sale of biopolymers on the terms and conditions set forth in the Commercial Alliance Agreement.  In 2006, ADM exercised this Option, and the Technology Alliance and Option Agreement concluded.

 

The Commercial Alliance Agreement between Metabolix and ADM Polymer specified the terms and structure of the alliance. The primary function of this agreement was to establish the activities and obligations of the parties to commercialize PHA biopolymers, which have been marketed under the brand names Mirel™ and MveraTM.  These activities included: the establishment of a joint venture company, Telles, LLC (“Telles”), to market and sell PHA biopolymers, the construction of a manufacturing facility capable of producing 110 million pounds of material annually (the “Commercial Manufacturing Facility”), the licensing of technology to Telles and to ADM, and the conducting of various research, development, manufacturing, sales and marketing, compounding and administrative services by the parties.

 

Telles was formed to: (i) serve as the commercial entity to establish and develop the commercial market for PHA biopolymers, and conduct the marketing and sales in accordance with the goals of the commercial alliance, (ii) assist in the coordination and integration of the manufacturing, compounding and marketing activities, and (iii) administer and account for financial matters on behalf of the parties.  Metabolix and ADM each had a 50% ownership and voting interest in Telles.

 

Under the Technology Alliance and Option Agreement and Commercial Alliance Agreement various payments were made to Metabolix by ADM as shown in the table below.  All of these payments were recorded as deferred revenue on the Company’s balance sheet and were expected to be recognized on a straight line basis over a period of approximately ten years in which Metabolix would fulfill its contractual obligations during the Commercial Phase of the Commercial Alliance Agreement.

 

Upfront payment		$	3,000
Milestone payments		2,000
Support payments		22,050
Cost sharing payments for pre-commercial manufacturing plant construction and operations		11,835
Total		$	38,885

 

Under the Commercial Alliance Agreement ADM was permitted, under limited circumstances, to terminate the alliance if a change in circumstances that was not reasonably within the control of ADM made the anticipated financial return from the project inadequate or too uncertain. The agreement provided that, upon termination by ADM due to a change in circumstances, we would be permitted to continue to produce and sell PHA biopolymers, and ADM would be required to perform manufacturing services for the Company for a period of time following the termination (subject to certain payment obligations to ADM).  On January 9, 2012, ADM notified us that it was terminating the commercial alliance effective February 8, 2012.  ADM had recently undertaken a strategic review of its business investments and activities and made the decision to focus resources outside of Telles. As the basis for the decision, ADM indicated to us that the projected financial returns from the alliance were too uncertain.

 

The Commercial Alliance Agreement with ADM limited the rights of both ADM and the Company to work with other parties or alone in developing or commercializing certain PHAs produced through fermentation. These exclusivity obligations ended upon termination of the alliance.  Also, upon termination of the alliance, Metabolix intellectual property licenses to ADM Polymer and Telles ended, with Metabolix retaining all rights to its intellectual property.  ADM retained its Commercial Manufacturing Facility located in Clinton, Iowa, previously used to produce PHA biopolymers for Telles.

 

Our Company has no further performance obligations in connection with the commercial alliance after its termination, and as a result, the $38,885 of deferred revenue was recognized by us during its fiscal quarter ended March 31, 2012.

 

18

Table of Contents

 

After termination of the Commercial Alliance Agreement, the parties entered into a Settlement Agreement dated March 6, 2012 in which the parties agreed to specific terms related to the winding up and dissolution of Telles.  Under this Settlement Agreement the Company purchased certain assets of the joint venture for $2,982, including all of Telles’s inventory, exclusive and perpetual rights to all of Telles’s trademarks, and all product registrations, certifications and approvals for Telles’s PHA biopolymers.  Pursuant to the Settlement Agreement, ADM relinquished any claims with respect to certain co-funded equipment previously acquired by Metabolix and situated at locations other than the Clinton, Iowa Commercial Manufacturing Facility, and Metabolix and Telles waived any rights to post-termination manufacturing and fermentation services under the Commercial Alliance Agreement. We assessed the market value of the various assets acquired from Telles under the Settlement Agreement and determined that the full amount of the $2,982 purchase price should be allocated to the raw material and biopolymer inventory.

 

Pursuant to the Settlement Agreement, Telles paid to ADM an amount equal to the aggregate cash balances of Telles totaling $3,778 on the date of the Settlement Agreement, minus $100 retained by Telles to settle any remaining trade obligations.  We believe the remaining trade obligations of Telles at the date of execution of the Settlement Agreement did not exceed $100.  In the event that ADM is required to repay to Telles or to pay to any creditor of Telles any amounts included in the $2,982 purchase price or the $3,678 distributed to ADM by Telles pursuant to the Settlement Agreement, we are obligated to reimburse ADM in an amount equal to 50% of such payments, provided that in no event would the amount to be so paid by us exceed the total of the $2,982 purchase price and the $3,678 Telles cash required to be so repaid or reimbursed by ADM. We are not aware of any such third party creditor claims, and we believe the likelihood that we will be required to reimburse ADM under this provision is remote and therefore no liability for this potential obligation is included in the Company’s balance sheet at June 30, 2012.

 

Government Grants

 

As of June 30, 2012, expected gross proceeds of $5,622 remain to be received under our U.S. and Canadian government grants, which includes amounts for reimbursement to our subcontractors, as well as reimbursement for our employees’ time, benefits and other expenses related to future performance.

 

The status of our United States and Canadian government grants is as follows:

 

				Total			Total received			Remaining amount
		Funding		Government			through			available as of			Contract/Grant
Program Title		Agency		Funds			June 30, 2012			June 30, 2012			Expiration
Renewable Enhanced Feedstocks For Advanced Biofuels And Bioproducts		Department of Energy		$	6,000		$	946		$	5,054		June 2014
Blow Molded Bioproducts From Renewable Plastics		Department of Agriculture		349			314			35			August 2012
Subcontract from University of Massachusetts (Amherst) project funded by ARPA-E entitled “Development of a Dedicated High Value Biofuels Crop”		Department of Energy		259			—			259			June 2013
Capacity Building for Commercial-Scale PHB Camelina Development		National Research Council Canada		254			—			254			March 2014
Advanced Technologies For Engineering of Camelina		Canadian Ministry of Agriculture		210			190			20			February 2013
Total				$	7,072		$	1,450		$	5,622

 

Critical Accounting Estimates and Judgments

 

The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. The preparation of these

 

19

Table of Contents

 

financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and six months ended June 30, 2012 are consistent with those discussed in Note 2 to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2011. The critical accounting policies and the significant judgments and estimates used in the preparation of our consolidated financial statements for the three and six months ended June 30, 2012 are consistent with those discussed in our Annual Report on Form 10-K for the year ended December 31, 2011 in the section captioned “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Estimates and Judgments.”

 

Results of Operations

 

Comparison of the Three Months Ended June 30, 2012 and 2011

 

Revenue

 

		Three Months Ended
		June 30,
		2012			2011			Change
Grant revenue		$	461		$	99		$	362
License fee and royalty revenue from related parties		89			92			(3		)
Product revenue		373			—			373
Total revenue		$	923		$	191		$	732

 

Total revenue was $923 and $191 for the three months ended June 30, 2012 and 2011, respectively. During the three months ended June 30, 2012, we recognized $461 of government grant revenue compared to $99 for the respective period in 2011.  Grant revenue for the three months ended June 30, 2012 primarily consisted of $366 in revenue earned from the Renewable Enhanced Feedstocks for Advanced Biofuels and Bioproducts (“REFABB”) grant awarded by the U.S. Department of Energy in mid-2011.  No revenue was recorded from this grant in the second quarter of 2011.  We also recognized $373 of product revenue from sales of biopolymer inventory, including some excess raw materials, acquired in March 2012 from our terminated Telles joint venture with ADM.  There was no product revenue recorded by Metabolix during the three months ended June 30, 2011 since sales of biopolymer prior to the termination of the joint venture were recorded by Telles.  As we implement sales terms in Q3 2012 that will allow a limited right of return on future product sales for a 60 day period, we anticipate that we will defer revenue until the expiration of that 60 day period.  Following the impact of these new sales terms in the period of adoption, we expect revenue will increase as we continue to commercialize Mirel and the product gains market acceptance.

 

Costs and expenses

 

		Three Months Ended
		June 30,
		2012			2011			Change
Cost of product revenue		$	437		$	—		$	437
Research and development		5,006			6,000			(994		)
Selling, general, and administrative		3,437			4,196			(759		)
Total costs and expenses		$	8,880		$	10,196		$	(1,316	)

 

Cost of Product Revenue

 

Cost of product revenue was $437 for the three months ended June 30, 2012.  Included in cost of product revenue is $130 related to inventory shipped to customers and $307 for freight, shipping supplies and warehouse costs for more than five million pounds of polymer and raw material owned by the Company as of June 30, 2012.  

 

20

Table of Contents

 

We anticipate warehousing costs will decline during 2012 as we sell product and achieve cost reductions through consolidation of inventory at less expensive locations.

 

Research and development expenses

 

Research and development expenses were $5,006 and $6,000 for the three months ended June 30, 2012 and 2011, respectively. The decrease of $994 was primarily due to a decrease in employee compensation and related benefit expenses, contract research and travel.  Employee compensation and related benefit expenses were $2,959 and $3,407 for the three months ended June 30, 2012 and 2011, respectively. The decrease of $448 was primarily attributable to a decrease in headcount in response to the termination of the Telles joint venture.  Expenses related to contract research decreased $423 primarily due to a reduction in support to the University of Massachusetts (Lowell) for biopolymer research, also resulting from the termination of the Telles joint venture. Travel expenses decreased $83 due primarily to lower headcount associated with product technical development activities.

 

We expect our research and development expenses to remain lower during 2012 as a result of the termination of our Telles joint venture in February 2012 and our subsequent decision to restructure our operations, primarily through employee termination. We retained a core team to provide continuity with the commercialization of our biopolymer technology and we will continue to evaluate options to launch the PHA biopolymers business with a new commercial model. We also expect to continue development of biobased industrial chemicals. In addition, we will continue to incur costs in support of government grants related to our crop program, including our REFABB grant, the object of which is the demonstration of low cost chemicals production from biomass crops and for the development of intellectual property in our oilseeds program.

 

Selling, general, and administrative expenses

 

Selling, general, and administrative expenses were $3,437 and $4,196 for the three months ended June 30, 2012 and 2011, respectively. The decrease of $759 was primarily due to a decrease in employee compensation and related benefit expenses, legal fees and travel. Employee compensation and related benefit expenses were $1,934 and $2,443 for the three months ended June 30, 2012 and 2011, respectively. The decrease of $509 is primarily attributable to reduction in headcount in response to the termination of the Telles joint venture.  Legal fees and expenses including general and patent related expenses decreased $188 for the three months ended June 30, 2012, compared to June 30, 2011. Travel expense decreased by $61 due to lower headcount.

 

We expect selling, general and administrative expenses to remain lower during 2012, primarily as a result of the termination of the Telles joint venture in February 2012 and our subsequent decision to restructure our operations, primarily through employee terminations. We anticipate that this will result in lower sales and marketing expenses.

 

Other Income (Net)

 

		Three Months Ended
		June 30,
		2012			2011			Change
Total other income (net)		$	9		$	23		$	(14	)

 

Other income (net) was $9 and $23 for the three months ended June 30, 2012 and 2011, respectively. Other income (net) during both periods consisted primarily of income from our investments.

 

21

Table of Contents

 

Comparison of the Six Months Ended June 30, 2012 and 2011

 

Revenue

 

		June 30,
		2012			2011			Change
Revenue from termination of ADM collaboration		$	38,885		$	—		$	38,885
Grant revenue		839			124			715
License fee and royalty revenue from related parties		134			393			(259		)
Product revenue		387			—			387
Total revenue		$	40,245		$	517		$	39,728

 

Total revenue was $40,245 and $517 for the six months ended June 30, 2012 and 2011, respectively. During the six months ended June 30, 2012, we recognized $38,885 of previously deferred revenue related to our Telles joint venture with ADM that terminated effective February 8, 2012.  This deferred revenue, which was previously expected to be recognized over a future estimated ten year period as we met our contractual performance obligations, became immediately recognizable upon termination when no further performance obligations remained.  Grant revenue was $839 and $124 for the six months ended June 30, 2012 and 2011, respectively. The increase of $715 primarily consisted of $681 in revenue earned from the REFABB grant awarded by the U.S. Department of Energy in mid-2011.  No revenue was recorded from this grant in the first half of 2011.  During the six months ended June 30, 2012 we recognized $134 of license fee and royalty revenue from related parties compared to $393 for the respective period in 2011. The decrease of $259 was primarily attributable to a royalty earned under a licensing agreement with Tepha, Inc. during the first quarter of 2011.  We also recognized $387 of product revenue from sales of Mirel biopolymer inventory acquired in March 2012 from our terminated Telles joint venture with ADM.  There was no product revenue during the six months ended June 30, 2011.

 

Costs and expenses

 

		June 30,
		2012			2011			Change
Cost of product revenue		$	492		$	—		$	492
Research and development		11,051			12,199			(1,148		)
Selling, general, and administrative		7,836			7,983			(147		)
Total costs and expenses		$	19,379		$	20,182		$	(803	)

 

Cost of Product Revenue

 

Cost of product revenue was $492 for the six months ended June 30, 2012.  Included in cost of product revenue is $135 related to inventory shipped to customers and $357 for freight, shipping supplies and warehouse costs for more than five million pounds of polymer and raw material owned by the Company as of June 30, 2012.   We anticipate warehousing costs will decline during 2012 as we sell product and achieve cost reductions through consolidation of inventory at less expensive locations.

 

Research and development expenses

 

Research and development expenses were $11,051 and $12,199 for the six months ended June 30, 2012 and 2011, respectively. The decrease of $1,148 was primarily attributable to decreases in employee compensation and related benefits, contracted research and travel partially offset by an increase in consulting services.  Employee compensation decreased to $6,617 for the six months ended June 30, 2012 compared to $7,103 for the respective period in 2011. The decrease of $486 was primarily due to the termination of the Telles joint venture. Contract research and service expenses were $400 and $1,003 for the six months ended June 30, 2012 and 2011, respectively.  The decrease of $603 was primarily attributable to lower expenses for contract research support to the University of Massachusetts (Lowell) for biopolymer research and development, a decrease in the number of polymer product trials and lower product testing service expense.  Travel expenses were $131 and $338 for the six months ended June 30, 2012 and 2011, respectively. The decrease of $207 was primarily the result of decreased travel related to product and technical development. Consulting services increased to $343 during the six months ended June 30, 2012 compared to $197 during the respective period in

 

22